New Results
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
View ORCID ProfileTheodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Lucy Penfold, Simon Ang, Alice Ormrod, Edward K. Ainscow, Ash K. Bahl, David Carling, View ORCID ProfileMatthew J. Fuchter, View ORCID ProfileSimak Ali, View ORCID ProfileCharlotte L. Bevan
doi: https://doi.org/10.1101/2022.06.29.497030
Theodora A. Constantin
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Anabel Varela-Carver
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Kyle K. Greenland
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Gilberto Serrano de Almeida
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Lucy Penfold
2MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom
Simon Ang
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Alice Ormrod
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Edward K. Ainscow
3Carrick Therapeutics, Nova UCD, Bellfield Innovation Park, Dublin 4, Ireland
Ash K. Bahl
3Carrick Therapeutics, Nova UCD, Bellfield Innovation Park, Dublin 4, Ireland
David Carling
2MRC London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom
Matthew J. Fuchter
4Department of Chemistry and Molecular Sciences Research Hub, Imperial College London, White City Campus, London, United Kingdom
Simak Ali
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Charlotte L. Bevan
1Imperial Centre for Translational and Experimental Medicine, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, United Kingdom
Posted June 29, 2022.
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Lucy Penfold, Simon Ang, Alice Ormrod, Edward K. Ainscow, Ash K. Bahl, David Carling, Matthew J. Fuchter, Simak Ali, Charlotte L. Bevan
bioRxiv 2022.06.29.497030; doi: https://doi.org/10.1101/2022.06.29.497030
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Theodora A. Constantin, Anabel Varela-Carver, Kyle K. Greenland, Gilberto Serrano de Almeida, Lucy Penfold, Simon Ang, Alice Ormrod, Edward K. Ainscow, Ash K. Bahl, David Carling, Matthew J. Fuchter, Simak Ali, Charlotte L. Bevan
bioRxiv 2022.06.29.497030; doi: https://doi.org/10.1101/2022.06.29.497030
Subject Area
Subject Areas
- Biochemistry (11745)
- Bioengineering (8751)
- Bioinformatics (29194)
- Biophysics (14971)
- Cancer Biology (12095)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18305)
- Genetics (12245)
- Genomics (16801)
- Immunology (11867)
- Microbiology (28083)
- Molecular Biology (11592)
- Neuroscience (60962)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2885)
- Systems Biology (7339)
- Zoology (1651)